Interventions
Which longevity interventions have human evidence?
This map organizes intervention coverage around concepts readers recognize. Availability, development stage, mechanism, evidence, safety, and meaningful outcomes remain separate judgments.
Five reader-facing groups
From daily habits to experimental biotechnology
Future records will make development stage obvious—available today, off-label, human trials, preclinical, theoretical, or unknown—without treating progress as proof of benefit.
Lifestyle, nutrition, and prevention
Exercise, nutrition and dietary patterns, fasting and caloric restriction, sleep and circadian health, and preventive medicine.
Evidence question: Was the intervention tested against a comparison, for long enough, in a relevant population, using a meaningful outcome?
Read the LIFTMOR explainer →Read the exercise explainer →Read the CALERIE brief →Read the sleep explainer →Read the PREDIMED analysis →Read the late-life mobility explainer →Read the meal-timing explainer →Read the hearing analysis →Read the FINGER analysis →Read the MIND trial analysis →Read the ACTIVE explainer → Read the smoking-cessation mortality analysis →Read the sauna mortality-association explainer →Read the colonoscopy screening analysis →Read the low-dose CT screening analysis →Read the PSA screening analysis →Approved, off-label, and experimental candidates
Future coverage may include mTOR inhibitors, metformin, senolytics, NAD-related compounds, GLP-1 drugs, and other candidates only when source-backed reporting exists.
Evidence question: What indication, population, dose, outcome, development stage, and safety context were actually studied?
Read the CBT-I evidence explainer →Read the CPAP cardiovascular analysis →Read the melatonin claim check →Read the shingles vaccine analysis →Read the high-dose flu explainer →Read the RSV vaccine analysis →Read the WHI hormone analysis →Read the HORIZON fracture analysis →Read the PEARL brief →Read the senolytics analysis →Read the metformin analysis →Read the GLP-1 analysis →Read the SPRINT analysis →Read the statin explainer →Read the TRAVERSE cardiovascular analysis →Read the TRAVERSE fracture explainer →Read the testosterone function claim check →Read the ASPREE disability-free survival analysis →Read the ASPREE cardiovascular and bleeding explainer →Read the ASPREE cancer follow-up explainer →Products with distinct evidence and quality questions
Supplements remain separate from pharmaceuticals because regulation, label accuracy, product quality, dosing, and evidence require different scrutiny.
Evidence question: Is the evidence about an ingredient, a specific formulation, a biomarker, or a meaningful health outcome?
Read the NAD precursor claim check →Read the creatine brief →Read the omega-3 claim check →Read the vitamin D claim check →Read the multivitamin analysis →Read the resveratrol explainer → Read the spermidine cognition explainer →Read the urolithin A analysis →Read the GlyNAC claim check →Gene, RNA, cell, and regenerative approaches
Partial reprogramming, gene and RNA therapies, stem and immune cells, tissue regeneration, plasma factors, organ replacement, and bioprinting.
Evidence question: Was the work performed in cells, animals, or humans, and what efficacy, durability, delivery, control, and safety gaps remain?
Read the reprogramming analysis →Clocks, biomarkers, wearables, imaging, and diagnostics
Measurement tools can describe a signal without showing that changing the signal improves function, healthspan, or lifespan.
Evidence question: Is the measurement reliable, validated, actionable, and connected to an outcome that matters?
Understand epigenetic clocks → Read the cold-water thermogenesis analysis →Read the hyperbaric-oxygen biomarker explainer →How future pages will read
Five questions that separate a treatment from a longevity claim
- Stage
- Availability and development progress—not efficacy.
- Mechanism
- What researchers think it affects—not automatically what it achieves.
- Evidence
- Outcome- and population-specific support, limitations, conflicts, and uncertainty.
- Safety
- Known risks, unknowns, regulatory context, and tradeoffs kept visible.
Continue exploring